Sorrento Therapeutics Inc Share Price Other OTC
Equities
US83587F1030
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
04-10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
03-15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
Sales 2021 | 52.9M 4.17B | Sales 2022 | 62.84M 4.95B | Capitalization | 411M 32.43B |
---|---|---|---|---|---|
Net income 2021 | -428M -33.74B | Net income 2022 | -573M -45.17B | EV / Sales 2021 | 29.1 x |
Net Debt 2021 | 111M 8.73B | Net Debt 2022 | 84.53M 6.66B | EV / Sales 2022 | 7.89 x |
P/E ratio 2021 |
-3.2
x | P/E ratio 2022 |
-0.65
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.77% |
Managers | Title | Age | Since |
---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 59 | 31/12/88 |
Shawn Sahebi
COO | Chief Operating Officer | - | - |
Mike A. Royal
CTO | Chief Tech/Sci/R&D Officer | 70 | 02/03/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kim D. Janda
BRD | Director/Board Member | 67 | 31/03/12 |
David Lemus
BRD | Director/Board Member | 61 | 30/09/17 |
Jaisim Shah
BRD | Director/Board Member | 63 | 10/09/13 |
1st Jan change | Capi. | |
---|---|---|
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |